Disolf (DLBS1033) / Dexa Medica Group - LARVOL DELTA

Oral fibrinolytic agent in hyper-coagulopathy in severe COVID - 19 ARDS Patients: two case reports. (PubMed, J Pak Med Assoc) - "Our two case reports were the first that showed good clinical outcome and safety of DLBS1033 treatment in addition to fondaparinux for hypercoagulopathy therapy."

Journal • Acute Respiratory Distress Syndrome • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Cough • Diabetes • Heart Failure • Hematological Disorders • Hypertension • Infectious Disease • Novel Coronavirus Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Venous Thromboembolism

ADDLIST: DLBS1033 for Acute Ischemic Stroke Patients (clinicaltrials.gov) - P2/3 | N=80 | Terminated | Sponsor: Dexa Medica Group | The Study Sites classified as tertiary referral hospital. Therefore, patients being referred to the site are mostly those with comorbidities included in the exclusion criteria.

Enrollment change • Trial completion date • Trial termination • Cardiovascular • Ischemic stroke

Effect of DLBS1033 After Primary PCI in Patients With STE-ACS (clinicaltrials.gov) - P2/3 | N=23 | Terminated | Sponsor: Dexa Medica Group | N=40 ➔ 23 | Trial completion date: Sep 2023 ➔ Mar 2023 | Recruiting ➔ Terminated; The investigational cases were no longer relevant considering the recent implementation of our current national healthcare system.

Enrollment change • Trial completion date • Trial termination • Acute Coronary Syndrome • Cardiovascular • Myocardial Infarction

ADDLIST: DLBS1033 for Acute Ischemic Stroke Patients (clinicaltrials.gov) - P2/3 | N=160 | Active, not recruiting | Sponsor: Dexa Medica Group | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular • Ischemic stroke

Effect of DLBS1033 After Primary PCI in Patients With STE-ACS (clinicaltrials.gov) - P2/3 | N=40 | Recruiting | Sponsor: Dexa Medica Group | Trial completion date: Mar 2022 ➔ Sep 2023 | Trial primary completion date: Dec 2021 ➔ Jan 2023

Trial completion date • Trial primary completion date • Acute Coronary Syndrome • Cardiovascular • Myocardial Infarction

Effect of DLBS1033 on Functional Outcomes for Patients with Acute Ischemic Stroke: A Randomized Controlled Trial. (PubMed, Stroke Res Treat) - "The control group received standard therapy consisting of aspirin 100 mg once daily, atorvastatin 20 mg once daily, and vitamin B 100 mg three times daily. There was no clinically significant adverse event related to the study product. DLBS1033 in addition to the standard care was more effective in improving functional status compared to standard care alone in acute ischemic stroke patients with a similar safety profile."

Clinical • Journal • Cardiovascular • Ischemic stroke

Effect of DLBS1033 After Primary PCI in Patients With STE-ACS (clinicaltrials.gov) - P2/3; N=40; Recruiting; Sponsor: Dexa Medica Group; Trial completion date: Apr 2021 ➔ Mar 2022; Trial primary completion date: Jan 2021 ➔ Dec 2021

Clinical • Trial completion date • Trial primary completion date • Acute Coronary Syndrome • Cardiovascular • Myocardial Infarction

Effect of DLBS1033 After Primary PCI in Patients With STE-ACS (clinicaltrials.gov) - P2/3; N=40; Recruiting; Sponsor: Dexa Medica Group; Trial completion date: Dec 2020 ➔ Apr 2021; Trial primary completion date: Sep 2020 ➔ Jan 2021

Clinical • Trial completion date • Trial primary completion date • Acute Coronary Syndrome • Cardiovascular • Myocardial Infarction • F2

ADDLIST: DLBS1033 for Acute Ischemic Stroke Patients (clinicaltrials.gov) - P2/3; N=160; Recruiting; Sponsor: Dexa Medica Group; Trial completion date: Feb 2021 ➔ Sep 2023; Trial primary completion date: Nov 2020 ➔ Mar 2023

Clinical • Trial completion date • Trial primary completion date • Cardiovascular • Ischemic stroke • Reperfusion Injury

The Benefit of Add On DLBS1033 for Ischemic Stroke Patient (clinicaltrials.gov) - P2/3; N=180; Recruiting; Sponsor: Duta Wacana Christian University

Clinical • New P2/3 trial • Cardiovascular • Ischemic stroke • Reperfusion Injury

Effect of DLBS1033 After Primary PCI in Patients With STE-ACS (clinicaltrials.gov) - P2/3; N=40; Recruiting; Sponsor: Dexa Medica Group

New P2/3 trial • Acute Coronary Syndrome • Biosimilar • Cardiovascular

Tabletting Process of Pellets Containing Bioactive Fraction DLBS1033F Isolated from Lumbricus rubellus: Challenge and Strategy. (PubMed) - "A set of studies confirmed the preserved physical shape of the pellets. In addition, in vitro release studies of the multiparticulate tablet in reassembling media of the gastrointestinal tract indicated the successful formulation of DLBS1033F as an enteric as well as sustained-release solid dosage form."

Journal • Biosimilar

DLBS1033 for Acute Ischemic Stroke Patients (clinicaltrials.gov) - P2/3; N=160; Recruiting; Sponsor: Dexa Medica Group; Trial primary completion date: Oct 2016 ->May 2016

Trial primary completion date • Biosimilar • Reperfusion Injury

Effect of DLBS1033 After Primary PCI in Patients With STE-ACS (clinicaltrials.gov) - P2/3; N=40; Recruiting; Sponsor: Dexa Medica Group; Trial completion date: Dec 2019 ➔ Dec 2020; Trial primary completion date: Sep 2019 ➔ Sep 2020

Clinical • Trial completion date • Trial primary completion date

ADDLIST: DLBS1033 for Acute Ischemic Stroke Patients (clinicaltrials.gov) - P2/3; N=160; Recruiting; Sponsor: Dexa Medica Group; Trial completion date: Feb 2019 ➔ Feb 2021; Trial primary completion date: Nov 2018 ➔ Nov 2020

Clinical • Trial completion date • Trial primary completion date